Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;70(12):921-931.
doi: 10.1111/pin.13023. Epub 2020 Sep 21.

Multiplex gene-panel testing for lung cancer patients

Yasushi Yatabe  1 , Kuniko Sunami  2 , Koichi Goto  3 , Kazuto Nishio  4 , Naoko Aragane  5 , Sadakatsu Ikeda  6 , Akira Inoue  7 , Ichiro Kinoshita  8 , Hideharu Kimura  9 , Tomohiro Sakamoto  10 , Miyako Satouchi  11 , Junichi Shimizu  12 , Koji Tsuta  13 , Shinichi Toyooka  14 , Kazumi Nishino  15 , Yutaka Hatanaka  16 , Shingo Matsumoto  3 , Masashi Mikubo  17 , Tomoyuki Yokose  18 , Hirotoshi Dosaka-Akita  19
Affiliations
Review

Multiplex gene-panel testing for lung cancer patients

Yasushi Yatabe et al. Pathol Int. 2020 Dec.

Abstract

The year 2019 was considered to be the first year of cancer genome medicine in Japan, with three gene-panel tests using next-generation sequencing (NGS) techniques being introduced into clinical practice. Among the three tests, the Oncomine CDx Target test was approved under the category of regular molecular testing for lung cancer, which meant that this test could be used to select patients for molecularly targeted drugs. Conversely, the other two tests, NCC OncoPanel and FoundationOne CDx, were assigned to be used under the National Cancer Genome Medicine Network, and implementation was restricted to patients for whom standard treatment was completed or expected to be completed. These NGS tests can detect a series of genetic alterations in individual tumors, which further promotes the development of therapeutic agents and elucidates molecular pathways. The NGS tests require appropriate tissue size and tumor cell content, which can be accessed only by pathologists. In this report, we review the current reimbursement schema in our national healthcare policy and the requirements of the specimens for NGS testing based on the recently published 'Guidance of Gene-panel Testing Using Next-Generation Sequencers for Lung Cancer', by the Japanese Society of Lung Cancer.

Keywords: gene-panel test; lung cancer; molecular testing; next-generation sequencing.

PubMed Disclaimer

References

REFERENCES

    1. Vargas AJ, Harris CC. Biomarker development in the precision medicine era: Lung cancer as a case study. Nat Rev Cancer 2016; 16: 525-37.
    1. Lindeman NI, Cagle PT, Aisner DL et al. Updated Molecular Testing Guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 2018; 13: 323-58.
    1. Clinical Guidance of multiplex gene-panle testing using next-generation sequencing (in Japanese). 2017. Available from: https://www.jca.gr.jp/researcher/topics/2017/files/20171013.pdf
    1. Sunami K, Takahashi H, Tsuchihara K et al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0). Cancer Sci 2018; 109: 2980-85.
    1. Guidance to multiplex gene-panel testing using next-generation sequencers in lung cancer patients (in Japanese). 2019. Available from: https://www.haigan.gr.jp/uploads/files/NGS%E3%82%AC%E3%82%A4%E3%83%89%E3...

LinkOut - more resources